诉讼案件概述 - 针对Iovance Biotherapeutics公司提起集体诉讼 指控其在2024年8月8日至2025年5月8日期间涉嫌证券欺诈 [1] - 诉讼旨在为受影响的投资者挽回损失 [1] 指控内容 - 公司在集体诉讼期间向投资者提供过度乐观的陈述 同时被指控散布重大虚假和误导性声明 和/或隐瞒重大不利事实 [2] - 公司被指控不具备通过其批准的治疗中心网络产生和推动需求的能力 或无法利用其治疗方法的现有需求 [2] 财务表现与股价影响 - 2024年7月25日 公司公布2024财年第二季度财务业绩 并下调2024财年全年收入指引 [2] - 业绩下滑和指引下调归因于：1) iCTC设备年度维护导致产能减少超过一半约1个月 2) Proleukin销售额低于预期 3) 治疗中心开始治疗患者的速度不稳定 [2] - 消息公布后 公司股价从2025年5月8日收盘价3.17美元/股暴跌至2025年5月9日1.75美元/股 单日跌幅达44.795% [2] 律所背景 - Levi & Korsinsky律所在过去20年中为受损股东追回数亿美元赔偿 在证券集体诉讼领域有丰富经验 [4] - 该律所连续7年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 拥有70多名员工的专业团队 [4]

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=148839&from=4CLASS PERI ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between August 8, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeut ...

诉讼案件概述 - 罗森律师事务所宣布代表在2024年5月9日至2025年5月8日期间购买Iovance Biotherapeutics证券的股东提起集体诉讼 [1] - 诉讼指控被告在集体诉讼期间作出虚假和误导性陈述或未披露关键信息 [4] 指控内容 - 新授权的治疗中心(ATCs)在开始使用Amtagvi治疗患者时面临更长时间延迟 [4] - Iovance销售团队和新ATCs在患者识别和选择方面效率低下导致患者流失率上升 [4] - 上述问题导致成本增加和收入下降因为ATCs无法跟上产品制造速度 [4] - 被告对Iovance业务运营和前景的积极陈述因此缺乏合理基础并具有重大误导性 [4] 诉讼参与方式 - 投资者可通过罗森律师事务所网站或联系Phillip Kim律师参与集体诉讼 [3][6] - 投资者需在2025年7月14日前向法院申请成为首席原告 [1][3] - 首席原告将代表其他集体成员指导诉讼 [3] 律师事务所背景 - 罗森律师事务所在证券集体诉讼领域具有丰富经验专注于投资者权益保护 [5] - 该律所曾创下针对中国公司的最大证券集体诉讼和解记录 [5] - 2017年被ISS证券集体诉讼服务评为和解数量第一律所2013年以来每年排名前四 [5] - 2019年为投资者追回超过4.38亿美元2020年创始合伙人被Law360评为原告律师界泰斗 [5]

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025. SO WHAT: If you purchased Iovance securities during the Cla ...

公司财务表现 - 2025年第一季度总产品收入为4930万美元 较上一季度的7370万美元显著下降 [5] - 2025财年全年产品收入指引从4.5亿-4.75亿美元大幅下调至2.5亿-3亿美元 中值降幅超40% [5] 股价变动 - 2025年5月9日股价单日下跌1.42美元 跌幅达44.8% 收盘价1.75美元 [6] 诉讼指控内容 - 被指控在2024年5月9日至2025年5月8日期间做出重大虚假/误导性陈述 [4] - 未披露新授权治疗中心启动Amtagvi治疗的时间延迟问题 [4] - 销售团队和授权治疗中心在患者识别和选择方面效率低下 导致患者流失率上升 [4] - 上述问题导致成本上升和收入下降 因治疗中心无法消化生产的产品 [4] 公司解释 - 下调收入指引系反映Amtagvi近期上市动态 [5] - 更新后的预测考虑了授权治疗中心增长轨迹和新中心治疗时间线的实际经验 [5] 法律程序 - 联邦证券集体诉讼的牵头原告申请截止日期为2025年7月14日 [2] - 律师事务所自1995年成立以来已为投资者追回数亿美元 [3]

NEW YORK, May 17, 2025 /PRNewswire/ -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance  Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company's stockholders.For a free consultation, please visit https://julieholleman.com/iovance-biotherapeutics-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].According to a complaint recently filed in federal court, Iova ...

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.For more information, submit a form, email attorney Aaron Dumas, ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). Inve ...